THROMBOEMBOLIC COMPLICATIONS DURING AND AFTER CORTISONE AND ACTH THERAPY

By S. FAZLULLAH, M.B. (Osmania), D.T.M. & H.
Medical Registrar, Barrow-in-Furness group of Hospitals, Lancashire

Now cortisone is available to be prescribed freely by doctors in the United Kingdom, it is considered justifiable to report thromboembolic complications during and after cessation of cortisone and ACTH therapy.

These complications may not be serious but may be fatal due to sudden unpredictable pulmonary embolism.

In the presented clinical material, thromboembolic complications were observed during cortisone therapy, and after termination of ACTH. Three patients were treated promptly by anticoagulants with complete recovery.

Material

During 1954-55 nearly 150 patients received cortisone and ACTH for various conditions. Four of those patients developed thromboembolic complications. Two patients had thromboembolism during cortisone administration, and two after termination of ACTH. These four patients developed deep venous thrombosis in the legs, followed by pulmonary embolism. Three were up and about during this episode and the one cortisone case was in bed but freely mobile, with good general condition. One patient had silent deep pelvic vein thrombosis, the existence of which

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age</th>
<th>Sex</th>
<th>Disease</th>
<th>Doses</th>
<th>Time of Thromboembolism</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57</td>
<td>Male</td>
<td>Landry-Guillain-Barre syndrome</td>
<td>(a) Cortisone: 300 mg. 1st day 200 mg. 2nd day 100 mg. daily for 2 weeks (b) ACTH gel. (Armour): 60U b.d. 2 wks.</td>
<td>5th week after cessation of ACTH; deep venous thrombosis in legs and pulmonary embolism</td>
<td>Recovered by anticoagulants</td>
</tr>
<tr>
<td>2</td>
<td>59</td>
<td>Male</td>
<td>ditto</td>
<td>ACTH gel. (Armour): 60U b.d. for 1 wk.</td>
<td>2nd week after cessation of ACTH; deep venous thrombosis in the legs and pulmonary embolism</td>
<td>ditto</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>Female</td>
<td>Systemic lupus (pulmonary)</td>
<td>ACTH gel. (Armour): 60U b.d. for 1 wk. Cortisone 100 mg. daily for 6 wks. maintenance; 25-12.5 mg. daily for 3 months I.M. cortisone 1,500 mg. in divided doses in 2 weeks, pre-post-operative. Oral cortisone 50 mg. daily for 4 weeks D.O.C.A. 350 mg. in 4 weeks</td>
<td>During 1st wk., femoral vein thrombosis and pulmonary embolism</td>
<td>Recovered by anticoagulants</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>Female</td>
<td>Post-adrenalectomy state</td>
<td></td>
<td>6th week, thrombosis</td>
<td>Sudden death</td>
</tr>
</tbody>
</table>

SUMMARY OF PATIENTS STUDIED
was revealed by post-mortem examination. She had a fatal pulmonary embolism, so suddenly that there was no time to administer anticoagulants and other supportive measures.

The age of these patients was between 50-59 years, two were men and two women.

Onset: Two patients developed thromboembolism during cortisone therapy, one within the first week and the other in the fourth week. The other two cases manifested thromboembolism, two to five weeks after termination of ACTH (one in the second and the other in the fifth week)

Discussion

Thromboembolic complications during and after cortisone and ACTH therapy may be
serious in some cases due to 'silent' deep venous thrombosis which can be missed easily. Sudden fatal pulmonary embolism may then reveal the existence of such complications. Case No. 4 developed silent pelvic venous thrombosis which killed the patient by a sudden pulmonary embolism, which was confirmed by post-mortem examination. In such patients there is a possibility that already existing incipient venous thrombosis may be aggravated by cortisone, or that thrombophlebitis without pain can develop in patients receiving hormones.

**Mechanism of Venous Thrombosis**

The effects of these hormones on the various blood coagulation factors are not definitely known. Smith et al. (1950) described an anticoagulant action of the hormone. Cosgriff et al. (1950) described 'hyper-coagulability' of blood during therapy with these hormones. Cosgriff (1951) reported 40 thromboembolic episodes in 28 patients, in a study of 700 cases having cortisone and ACTH for various diseases. In his series, these complications included deep and superficial venous thrombosis, pulmonary embolism, cerebral thrombosis and thrombophlebitis, 45% during and 55% after discontinuance of these hormones. He ascribed these complications to the hyper-coagulability of blood, demonstrable within 48 hours of starting ACTH or cortisone, persisting as long as three weeks after termination of these hormones. In Case No. 2, thromboembolism occurred within the first week of cortisone therapy and in Cases 1 and 2 on the fifth and second week, after cessation of ACTH. Cosgriff (1951) thinks that thromboembolism after cessation of these hormones is due to persisting hyper-adrenalism and consequently an increased tendency for coagulation of blood. These may be the sequence of events, especially after higher doses of ACTH and long-acting I.M. cortisone.

Recently Chatterjea and Salomon (1954) observed that during cortisone and ACTH therapy, higher doses of anticoagulants are needed to keep the prothrombin time at the optimum level and they also described the antagonistic action of these hormones on anticoagulants activity.

**Prevention**

Thromboembolic complications are liable to occur mostly in those patients with the underlying localized or generalized vascular disease, with history of previous thromboembolism, and in cases confined to bed.

It may be wise to give a course of anticoagulants as a prophylactic measure during and 3 to 6 weeks after cessation of these hormones, especially after high doses of ACTH. This will prevent fatal unpredictable pulmonary embolism due to silent deep venous thrombosis.

**Summary**

1. Four patients with thromboembolism during and after cessation of cortisone and ACTH therapy have been described. Three were treated by anticoagulants.
2. The mechanism of the thromboembolism has been discussed and preventive measures outlined.

**Acknowledgment**

I am thankful to Dr. A. P. B. Waind and Mr. A. W. B. Strahan, consultants, North Lonsdale Hospital, Barrow-in-Furness, for providing facility to study these cases.

**Addendum**

Since this paper was written, two more cases with thromboembolic complications were observed during the administration of cortisone and ACTH. On the institution of the anticoagulants wide fluctuation of plasma prothrombin was noted, compared with that seen in control patients, not receiving these hormones. Patients receiving these hormones need larger doses of the anticoagulants to maintain the prothrombin time at the therapeutic level, compared with the control patients, having no cortisone or ACTH.

**Case 5**

Female, aged 45 years, with spontaneous disseminated myelitis had cortisone 3,000 mg. and ACTH 380 units Gel. in divided doses for two weeks. At the end of the second week she developed phlebothrombosis of the right leg, which was subsided by the administration of anticoagulants.

**Case 6**

Female, aged 47 years, with postadrenalectomy state, had cortisone 1,450 mg. in divided doses for three weeks. At the end of the third week she developed pulmonary embolism. She recovered by the administration of anticoagulants.

These cases were up and about during these complications.

(I wish to record my thanks to Dr. L. Watson and Mr. J. A. Rhind, consultants, General Infirmary, Pontefract, Yorks., for allowing me to treat these cases.)

**BIBLIOGRAPHY**


Thromboembolic Complications during and after Cortisone and Acth Therapy
S. Fazlullah

*Postgrad Med J* 1956 32: 444-446
doi: 10.1136/pgmj.32.371.444

Updated information and services can be found at:
http://pmj.bmj.com/content/32/371/444.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/